Cytokine networks and T-cell subsets in inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 22, Issue 5, 2016, Pages 1157-1167

  Chen, Mei Lan ^a   Sundrud, Mark S ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CD4+ T cells; Crohn's disease; cytokines; inflammation; inflammatory bowel disease; mucosal immunology; Regulatory T cells; Th1; Th17; Th2; ulcerative colitis

Indexed keywords

CYTOKINE;

CD4+ T LYMPHOCYTE; CROHN DISEASE; HUMAN; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; MOUSE;

ANIMALS; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; MICE; T-LYMPHOCYTE SUBSETS;

EID: 84964883210     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000714     Document Type: Review

References (172)

1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012; 380: 1590-1605
2. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621
3. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012; 380: 1606-1619
4. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142: 46-54
5. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015; 12: 720-727
6. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity. 2014; 40: 843-854
7. Loddo I, Romano C. Inflammatory bowel disease: genetics, Epigenetics, and pathogenesis. Front Immunol. 2015; 6: 551
8. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010; 16: 90-97
9. Davidson NJ, Leach MV, Fort MM, et al. T helper cell 1-Type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med. 1996; 184: 241-251
10. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006; 25: 309-318
11. Eun CS, Mishima Y, Wohlgemuth S, et al. Induction of bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10-/- mice. Infect Immun. 2014; 82: 2239-2246
12. Devkota S, Chang EB. Interactions between diet, Bile acid Metabolism, gut microbiota, and inflammatory bowel diseases. Dig Dis. 2015; 33: 351-356
13. Van Der Heide F, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 1199-1207
14. Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-Analysis. Am J Gastroenterol. 2014; 109: 1728-1738
15. Vince A, Dyer NH, O'Grady FW, et al. Bacteriological studies in Crohn's disease. J Med Microbiol. 1972; 5: 219-229
16. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007; 104: 13780-13785
17. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014; 15: 382-392
18. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011; 145: 745-757
19. Lahat G, Halperin D, Baraovsky E, et al. Immunomodulatory effects of ciprofloxacin in TNBS-induced colitis in mice. Inflamm Bowel Dis. 2007; 13: 557-565
20. Llopis M, Antolin M, Guarner F, et al. Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut. 2005; 54: 955-959
21. Gronbach K, Flade I, Holst O, et al. Endotoxicity of lipopolysaccharide as a determinant of T-cell-mediated colitis induction in mice. Gastroenterology. 2014; 146: 765-775
22. Kobayashi T, Steinbach EC, Russo SM, et al. NFIL3-deficient mice develop microbiota-dependent, IL-12/23-driven spontaneous colitis. J Immunol. 2014; 192: 1918-1927
23. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005; 128: 891-906
24. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature. 2012; 487: 104-108
25. Ayres JS, Trinidad NJ, Vance RE. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med. 2012; 18: 799-806
26. Guslandi M. Antibiotics for inflammatory bowel disease: do they work'. Eur J Gastroenterol Hepatol. 2005; 17: 145-147
27. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-Analysis. J Crohns Colitis. 2014; 8: 1569-1581
28. Ianiro G, Bibbo S, Scaldaferri F, et al. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine. 2014; 93: e97
29. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015; 149: 102-109.e106
30. Barnes SL, Vidrich A, Wang ML, et al. Resistin-like molecule beta (RELMbeta/FIZZ2) is highly expressed in the ileum of SAMP1/YitFc mice and is associated with initiation of ileitis. J Immunol. 2007; 179: 7012-7020
31. Bamias G, Marini M, Moskaluk CA, et al. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol. 2002; 169: 5308-5314
32. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998; 66: 5224-5231
33. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491: 119-124
34. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015; 12: 537-545
35. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476: 214-219
36. Cucca F, Goy JV, Kawaguchi Y, et al. A male-female bias in type 1 diabetes and linkage to chromosome Xp in MHC HLA-DR3-positive patients. Nat Genet. 1998; 19: 301-302
37. Bevan S, Popat S, Braegger CP, et al. Contribution of the MHC region to the familial risk of coeliac disease. J Med Genet. 1999; 36: 687-690
38. Kim TW, Seo JN, Suh YH, et al. Involvement of lymphocytes in dextran sulfate sodium-induced experimental colitis. World J Gastroenterol. 2006; 12: 302-305
39. Hoffmann JC, Peters K, Henschke S, et al. Role of T lymphocytes in rat 2, 4, 6-Trinitrobenzene sulphonic acid (TNBS) induced colitis: increased mortality after gammadelta T cell depletion and no effect of alphabeta T cell depletion. Gut. 2001; 48: 489-495
40. Hirano D, Kudo S. Usefulness of CD4+CD45RBhigh CD25- celltransferred SCID mice for preclinical evaluation of drugs for inflammatory bowel disease. J Pharmacol Sci. 2009; 110: 169-181
41. Ostanin DV, Bao J, Koboziev I, et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G135-G146
42. Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-Type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest. 2001; 107: 695-702
43. Haddley K. Vedolizumab for the treatment of inflammatory bowel disease. Drugs of Today. 2014; 50: 309-319
44. Gonzalez-Cabrera PJ, Brown S, Studer SM, et al. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014; 6: 109
45. Nakayamada S, Takahashi H, Kanno Y, et al. Helper T cell diversity and plasticity. Curr Opinion Immunol. 2012; 24: 297-302
46. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFNgamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157: 1261-1270
47. Matsuoka K, Inoue N, Sato T, et al. T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut. 2004; 53: 1303-1308
48. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-Associated immunopathologies. Immunity. 1999; 10: 387-398
49. Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015; 163: 367-380
50. Sano T, Huang W, Hall JA, et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid a to promote local effector Th17 responses. Cell. 2015; 163: 381-393
51. Ito H, Fathman CG. CD45RBhigh CD4+ T cells from IFN-gamma knockout mice do not induce wasting disease. J Autoimmun. 1997; 10: 455-459
52. Neurath MF, Weigmann B, Finotto S, et al. The transcription factor Tbet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med. 2002; 195: 1129-1143
53. Claesson MH, Bregenholt S, Bonhagen K, et al. Colitis-inducing potency of CD4+ T cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12 responsiveness, and CD45RB surface phenotype. J Immunol. 1999; 162: 3702-3710
54. Villarino AV, Artic D, Bezbradica JS, et al. IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD. Int Immunol. 2008; 20: 739-752
55. Awasthi A, Kuchroo VK. IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation. Nat Immunol. 2009; 10: 568-570
56. Reinisch W, De Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebocontrolled, multiple-dose study. Inflamm Bowel Dis. 2010; 16: 233-242
57. Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut. 2006; 55: 1138-1144
58. Halloran B, Chang J, Shih DQ, et al. Molecular patterns in human ulcerative colitis and correlation with response to infliximab. Inflamm Bowel Dis. 2014; 20: 2353-2363
59. Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol. 2015; 15: 57-65
60. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005; 129: 550-564
61. Karttunnen R, Breese EJ, Walker-Smith JA, et al. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J Clin Pathol. 1994; 47: 1015-1018
62. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995; 101: 428-435
63. Kucharzik T, Lugering N, Adolf M, et al. Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease. Dig Dis Sci. 1997; 42: 805-812
64. Mann ER, Bernardo D, Ng SC, et al. Human gut dendritic cells drive aberrant gut-specific t-cell responses in ulcerative colitis, characterized by increased IL-4 production and loss of IL-22 and IFNgamma. Inflamm Bowel Dis. 2014; 20: 2299-2307
65. Boirivant M, Fuss IJ, Chu A, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998; 188: 1929-1939
66. Iijima H, Takahashi I, Kishi D, et al. Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. J Exp Med. 1999; 190: 607-615
67. Okuda Y, Takahashi I, Kim JK, et al. Development of colitis in signal transducers and activators of transcription 6-deficient T-cell receptor alpha-deficient mice: a potential role of signal transducers and activators of transcription 6-independent interleukin-4 signaling for the generation of Th2-biased pathological CD4+ betabetaT cells. Am J Pathol. 2003; 162: 263-271
68. Rosen MJ, Chaturvedi R, Washington MK, et al. STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. J Immunol. 2013; 190: 1849-1858
69. Okamura M, Yoh K, Ojima M, et al. Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis. Exp Anim. 2014; 63: 133-140
70. Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol. 2008; 26: 261-292
71. Levo Y, Shalit M, Wollner S, et al. Serum IgE levels in patients with inflammatory bowel disease. Ann Allergy. 1986; 56: 85-87
72. O'Donoghue DP, Kumar P. Rectal IgE cells in inflammatory bowel disease. Gut. 1979; 20: 149-153
73. Hoving JC, Kirstein F, Nieuwenhuizen NE, et al. B cells that produce immunoglobulin E mediate colitis in BALB/c mice. Gastroenterology. 2012; 142: 96-108
74. Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015; 75: 68-78
75. Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006; 12: 99-106
76. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015; 15: 271-282
77. Griseri T, Arnold IC, Pearson C, et al. Granulocyte macrophage colonystimulating factor-Activated eosinophils promote interleukin-23 driven chronic colitis. Immunity. 2015; 43: 187-199
78. Camelo A, Barlow JL, Drynan LF, et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol. 2012; 47: 1198-1211
79. Waddell A, Vallance JE, Moore PD, et al. IL-33 signaling protects from murine oxazolone colitis by supporting intestinal epithelial function. Inflamm Bowel Dis. 2015. doi: 10.1097/MIB.0000000000000532
80. Danese S, Rudzi-nski J, Brandt W, et al. Tralokinumab for moderateto- severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut. 2015; 64: 243-249
81. Spiess C, Bevers J III, Jackman J, et al. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem. 2013; 288: 26583-26593
82. Kasaian MT, Page KM, Fish S, et al. Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice. Immunology. 2014; 143: 416-427
83. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003; 421: 744-748
84. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol. 2009; 27: 485-517
85. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006; 126: 1121-1133
86. Jiang W, Su J, Zhang X, et al. Elevated levels of Th17 cells and Th17- related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res. 2014; 63: 943-950
87. Olsen T, Rismo R, Cui G, et al. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 2011; 56: 633-640
88. Mudter J, Wirtz S, Galle PR, et al. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis. Pathobiology. 2002; 70: 170-176
89. Durant L, Watford WT, Ramos HL, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010; 32: 605-615
90. Leppkes M, Becker C, Ivanov II, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2009; 136: 257-267
91. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61: 1693-1700
92. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-To-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013; 168: 412-421
93. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-To-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013; 168: 402-411
94. Keijsers RR, Joosten I, Van Erp PE, et al. Cellular sources of IL-17 in psoriasis: a paradigm shift'. Exp Dermatol. 2014; 23: 799-803
95. Montaldo E, Juelke K, Romagnani C. Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice. Eur J Immunol. 2015; 45: 2171-2182
96. Wang CQ, Akalu YT, Suarez-Farinas M, et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol. 2013; 133: 2741-2752
97. Reynolds JM, Martinez GJ, Nallaparaju KC, et al. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J Immunol. 2012; 189: 4226-4230
98. Song X, Dai D, He X, et al. Growth factor FGF2 Cooperates with interleukin-17 to repair intestinal epithelial damage. Immunity. 2015; 43: 488-501
99. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235-238
100. Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T (H)17 cells in the absence of TGF-beta signalling. Nature. 2010; 467: 967-971
101. Lee Y, Laurence A, Yang XP, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012; 13: 991-999
102. Esplugues E, Huber S, Gagliani N, et al. Control of TH17 cells occurs in the small intestine. Nature. 2011; 475: 514-518
103. Cosmi L, Maggi L, Santarlasci V, et al. T helper cells plasticity in inflammation. Cytometry A. 2014; 85: 36-42
104. Sundrud MS, Trivigno C. Identity crisis of Th17 cells: many forms, many functions, many questions. Semin Immunol. 2013; 25: 263-272
105. Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006; 203: 2473-2483
106. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006; 203: 2673-2682
107. Kleinschek MA, Boniface K, Sadekova S, et al. Circulating and gutresident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med. 2009; 206: 525-534
108. Mitson-Salazar A, Yin Y, Wansley DL, et al. Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human T2 cell subpopulation with enhanced function. J Allergy Clin Immunol. 2015. doi: 10.1016/j.jaci.2015.08.007
109. Pesenacker AM, Bending D, Ursu S, et al. CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood. 2013; 121: 2647-2658
110. Ramesh R, Kozhaya L, McKevitt K, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014. doi: 10.1084/jem.20130301
111. Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest. 2013; 123: 4131-4133
112. Schinkel AH, Smit JJ, Van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994; 77: 491-502
113. Ludescher C, Thaler J, Drach D, et al. Detection of activity of Pglycoprotein in human tumour samples using rhodamine 123. Br J Haematol. 1992; 82: 161-168
114. Annese V, Valvano MR, Palmieri O, et al. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-Analysis. World J Gastroenterol. 2006; 12: 3636-3644
115. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998; 161: 5733-5744
116. Yates CR, Chang C, Kearbey JD, et al. Structural determinants of Pglycoprotein- mediated transport of glucocorticoids. Pharm Res. 2003; 20: 1794-1803
117. Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015; 521: 222-226
118. Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an antiinterleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015; 173: 930-939
119. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006; 116: 1310-1316
120. Codarri L, Gyülvészi G, Tosevski V, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011; 12: 560-567
121. Berstad A, Borkje B, Riedel B, et al. Increased fecal eosinophil cationic protein in inflammatory bowel disease. Hepatogastroenterology. 1993; 40: 276-278
122. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30: 531-564
123. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27: 20-21
124. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27: 68-73
125. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol. 2003; 170: 3939-3943
126. Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2001; 2: 301-306
127. Lathrop SK, Bloom SM, Rao SM, et al. Peripheral education of the immune system by colonic commensal microbiota. Nature. 2011; 478: 250-254
128. Marie JC, Letterio JJ, Gavin M, et al. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005; 201: 1061-1067
129. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992; 359: 693-699
130. Travis MA, Sheppard D. TGF-beta activation and function in immunity. Annu Rev Immunol. 2014; 32: 51-82
131. Travis MA, Reizis B, Melton AC, et al. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature. 2007; 449: 361-365
132. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113: 685-700
133. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001; 108: 601-609
134. Fantini MC, Rizzo A, Fina D, et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology. 2009; 136: 1308-1316. e1301-1303
135. Rizzo A, Waldner MJ, Stolfi C, et al. Smad7 expression in T cells prevents colitis-Associated cancer. Cancer Res. 2011; 71: 7423-7432
136. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006; 131: 1786-1798
137. Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther. 2012; 20: 870-876
138. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013; 504: 451-455
139. Round JL, Lee SM, Li J, et al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011; 332: 974-977
140. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010; 107: 12204-12209
141. Veltkamp C, Anstaett M, Wahl K, et al. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFalpha treatment. Gut. 2011; 60: 1345-1353
142. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2010; 30: 80-89
143. Wang Y, Liu XP, Zhao ZB, et al. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J Dig Dis. 2011; 12: 286-294
144. Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and antiinflammatory macrophage function. Immunity. 2014; 40: 706-719
145. Ishikawa D, Okazawa A, Corridoni D, et al. Tregs are dysfunctional in vivo in a spontaneous murine model of Crohn's disease. Mucosal Immunol. 2013; 6: 267-275
146. Ueno A, Jijon H, Chan R, et al. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013; 19: 2522-2534
147. Hovhannisyan Z, Treatman J, Littman DR, et al. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology. 2011; 140: 957-965
148. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008; 28: 546-558
149. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361: 2033-2045
150. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000; 119: 1461-1472
151. Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opinion Immunol. 2009; 21: 612-618
152. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007; 450: 566-569
153. Bardel E, Larousserie F, Charlot-Rabiega P, et al. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol. 2008; 181: 6898-6905
154. Fonseca-Camarillo G, Furuzawa-Carballeda J, Yamamoto-Furusho JK. Interleukin 35 (IL-35) and IL-37: intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine. 2015; 75: 389-402
155. Harrison OJ, Srinivasan N, Pott J, et al. Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3(+) Treg cell function in the intestine. Mucosal Immunol. 2015; 8: 1226-1236
156. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014; 513: 564-568
157. Palomo J, Dietrich D, Martin P, et al. The interleukin (IL)-1 cytokine family-balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015; 76: 25-37
158. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-Associated cytokines. Immunity. 2005; 23: 479-490
159. Yang J, Murphy TL, Ouyang W, et al. Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol. 1999; 29: 548-555
160. Leach ST, Messina I, Lemberg DA, et al. Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 68-74
161. Gerlach K, Hwang Y, Nikolaev A, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014; 15: 676-686
162. Gupta P, Gurudutta GU, Saluja D, et al. PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis. J Cell Mol Med. 2009; 13: 4349-4363
163. Demoulin JB, Van Snick J, Renauld JC. Interleukin-9 (IL-9) induces cell growth arrest associated with sustained signal transducer and activator of transcription activation in lymphoma cells overexpressing the IL-9 receptor. Cell Growth Differ. 2001; 12: 169-174
164. Nalleweg N, Chiriac MT, Podstawa E, et al. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut. 2015; 64: 743-755
165. Oh CK, Raible D, Geba GP, et al. Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma. Inflamm Allergy Drug Targets. 2011; 10: 180-186
166. Oh CK, Leigh R, McLaurin KK, et al. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res. 2013; 14: 93
167. Suh WK. Life of T follicular helper cells. Mol Cells. 2015; 38: 195-201
168. Choi YS, Kageyama R, Eto D, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. 2011; 34: 932-946
169. Liu X, Chen X, Zhong B, et al. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature. 2014; 507: 513-518
170. Sarra M, Monteleone I, Stolfi C, et al. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis. 2010; 16: 1332-1339
171. Yu J, He S, Liu P, et al. Interleukin21 promotes the development of ulcerative colitis and regulates the proliferation and secretion of follicular T helper cells in the colitides microenvironment. Mol Med Rep. 2015; 11: 1049-1056
172. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology. 2008; 134: 1038-1048